{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:52:34Z","timestamp":1785775954780,"version":"3.56.0"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chemotherapy\u2010induced nausea and vomiting (CINV) remains a prevalent treatment complication, often significantly impairing patients' quality of life and reducing adherence to chemotherapy regimens. The standard triplet antiemetic regimen, including either a neurokinin\u20101 (NK1) receptor antagonist (RA) or olanzapine, combined with a 5\u2010hydroxytryptamine type 3 (5\u2010HT3) RA and dexamethasone (DEX), faces challenges primarily due to DEX\u2010related adverse effects and its potential to compromise the efficacy of antitumor agents. This study assessed whether omitting DEX (F\u2010Group: olanzapine + 5\u2010HT3 RA) is non\u2010inferior to the standard D\u2010Group (olanzapine + 5\u2010HT3 RA\u2009+\u2009DEX). In this multi\u2010center, double\u2010blind, randomized phase III trial, 254 adults with malignant solid tumors (Eastern Cooperative Oncology Group [ECOG] 0\u20132) scheduled for highly emetogenic chemotherapy (HEC) were randomized 1:1 to the F\u2010Group or D\u2010Group. The primary endpoint was the complete response (CR; no emesis\/rescue medication) rate over 0\u2013120\u2009h, with a non\u2010inferiority margin of \u221215%. Secondary endpoints included CR and complete control (CC; no vomiting\/nausea\/rescue therapy) rates in acute (0\u201324\u2009h) and delayed (25\u2013120\u2009h) phases, safety, and quality of life. Overall CR rates were 68.6% (D\u2010Group) and 69.7% (F\u2010Group;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u2009.9658), demonstrating non\u2010inferiority. Acute phase CR rates were 88.4% versus 86.9% (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u2009.8643), and delayed phase CR rates were 69.4% versus 69.7% (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u2009.9999). CC rates were comparable across phases, with no new adverse reactions. The combination of a 5\u2010HT3 RA and olanzapine is as non\u2010inferior as the standard triplet regimen, providing an alternative option for patients receiving HEC. The trial was registered at\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    , number NCT05805800.\n                  <\/jats:p>","DOI":"10.1002\/ijc.70069","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T10:29:06Z","timestamp":1753871346000},"page":"131-139","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Randomized, double\u2010blind phase\n                    <scp>III<\/scp>\n                    trial of a dexamethasone\u2010free regimen for managing highly emetogenic chemotherapy\u2010induced nausea and vomiting"],"prefix":"10.1002","volume":"158","author":[{"given":"Shi","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Biotherapy, Cancer Center, West China Hospital &amp; State Key Laboratory of Biotherapy Sichuan University  Chengdu China"},{"name":"Department of Oncology Chengdu Jinniu District People's Hospital  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi\u2010Yan","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, Cancer Center, West China Hospital &amp; State Key Laboratory of Biotherapy Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong\u2010Wei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center Ziyang Central Hospital  Ziyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Abdominal Tumor Multimodality Treatment, Department of Radiation Oncology, Cancer Center, West China Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li\u2010Cong","family":"Deng","sequence":"additional","affiliation":[{"name":"Cancer Center Ziyang Central Hospital  Ziyang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, West China School of Public Health and West China Fourth Hospital Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi\u2010Gong","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, Cancer Center, West China Hospital &amp; State Key Laboratory of Biotherapy Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology The General Hospital of Western Theater Command  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi\u2010Hui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology The General Hospital of Western Theater Command  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui\u2010Dan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, Cancer Center, West China Hospital &amp; State Key Laboratory of Biotherapy Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe\u2010Ran","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, Cancer Center, West China Hospital &amp; State Key Laboratory of Biotherapy Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7042-718X","authenticated-orcid":false,"given":"Xing\u2010Chen","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Biotherapy, Cancer Center, West China Hospital &amp; State Key Laboratory of Biotherapy Sichuan University  Chengdu China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0438"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.6382"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(02)00543-2"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2015.12.317"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0893-133X(94)00129-N"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01399-1"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0378"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.suponc.2011.05.002"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.11504"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01570-3"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603048"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2291"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.0006"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030546"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101771"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-28-131"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31125"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00837"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834016654902"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx698"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515725"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30678-3"},{"key":"e_1_2_12_24_1","first-page":"32","article-title":"Updated MASCC\/ESMO Consensus Recommendations: prevention of radiotherapy\u2010 and chemoradiotherapy\u2010induced nausea and vomiting","volume":"2023","author":"Ruhlmann CH","year":"2023","journal-title":"Support Care Cancer"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.026351"},{"issue":"2","key":"e_1_2_12_27_1","first-page":"120","article-title":"The association between diabetes mellitus and depression","volume":"9","author":"B SV","year":"2016","journal-title":"J Med Life"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1019-4"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-017-1200-4"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1515442"},{"issue":"0","key":"e_1_2_12_31_1","first-page":"21","article-title":"Efficacy of neurokinin\u20101 receptor antagonists in the prevention of chemotherapy\u2010induced nausea and vomiting in patients receiving carboplatin\u2010based chemotherapy: a systematic review and meta\u2010analysis","volume":"124","author":"Massimo DM","year":"2018","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70069","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.70069","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.70069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:24:02Z","timestamp":1785774242000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.70069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"alternative-id":["10.1002\/ijc.70069"],"URL":"https:\/\/doi.org\/10.1002\/ijc.70069","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"2025-01-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}